Boston Scientific's heart failure lead:
This article was originally published in Clinica
Executive Summary
The Acuity Steerable left ventricular lead developed by Boston Scientific has gained Japanese approval, and may now be used with cardiac resynchronisation therapy (CRT) devices. The lead has a deflectable tip to aid placement in difficult-to-access branch vessels on the left side of the heart. It also provides physicians with four configurations for stimulating the left side of the heart, Boston said, which allows physicians to change the stimulation site noninvasively after implantation. The lead also received reimbursement approval from the Japanese National Health Insurance System. Natick, Massachusetts-based Boston plans to launch the product immediately in Japan.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.